Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis

Completed

• Conditions: Rheumatoid Arthritis

• Registration Number: NCT03832374
• Lead Sponsor: University Hospital Center of Martinique

Brief Summary

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs.

The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways.

Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-02
• Study First Submitted: 2018-10-29
• Study First Submitted QC: 2019-02-05
• Study First Posted: 2019-02-06
• Status Verified: 2022-03
• Primary Completion: 2022-03
• Study Completion: 2022-03
• Last Update Submitted: 2022-03-08
• Last Update Posted: 2022-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 77

Inclusion Criteria

• Patient with rheumatoid arthritis ACR/EULAR 2010
• Patient with a higher age or equal to 18
• Patient receiving social security
• Patient giving his free and informed written consent

Exclusion Criteria

• Patient with overlap syndrome with another autoimmune disease
• Patients with known severe cardiopulmonary pathology
• Woman who is pregnant and breast feeding
• Patient with language difficulties or understanding

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of the positivity of the anti citrullinated peptide antibodies and subtype	three years	Presence of one or more subtypes of anti citrullinated peptide antibodies in the serum of patients with interstitial pneumopathy associated with rheumatoid arthritis who would be absent

Secondary Outcome Measures

Name	Time	Method
Genetic analysis of the main mutations	three years	Presence of mutation TERT, RTEL1, PARN et SFTPC

Trial Locations

Locations (1)

CHU Martinique; 🇲🇶 Fort-de-France, Martinique